[go: up one dir, main page]

CL2014003430A1 - Método para producir una preparacion de inmunoglobulina con un rendimiento mejorado - Google Patents

Método para producir una preparacion de inmunoglobulina con un rendimiento mejorado

Info

Publication number
CL2014003430A1
CL2014003430A1 CL2014003430A CL2014003430A CL2014003430A1 CL 2014003430 A1 CL2014003430 A1 CL 2014003430A1 CL 2014003430 A CL2014003430 A CL 2014003430A CL 2014003430 A CL2014003430 A CL 2014003430A CL 2014003430 A1 CL2014003430 A1 CL 2014003430A1
Authority
CL
Chile
Prior art keywords
producing
improved performance
immunoglobulin preparation
immunoglobulin
preparation
Prior art date
Application number
CL2014003430A
Other languages
English (en)
Inventor
Leopold Bruckschwaiger
Sonja Svatos
Wolfgang Teschner
Harald Arno Butterweck
Thomas Gundinger
Reinhard Grausenburger
Azra Pljevljakovic
Hans-Peter Schwarz
Julia Nürnberger
Berhard Koelbl
Original Assignee
Baxter Int
Baxter Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42727304&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2014003430(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Baxter Int, Baxter Healthcare Sa filed Critical Baxter Int
Publication of CL2014003430A1 publication Critical patent/CL2014003430A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39516—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum from serum, plasma
    • A61K39/39525—Purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0026—Blood substitute; Oxygen transporting formulations; Plasma extender
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
    • B01D15/12—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to the preparation of the feed
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B01D15/361—Ion-exchange
    • B01D15/362—Cation-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B01D15/361—Ion-exchange
    • B01D15/363—Anion-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/42—Selective adsorption, e.g. chromatography characterised by the development mode, e.g. by displacement or by elution
    • B01D15/424—Elution mode
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/02—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising inorganic material
    • B01J20/10—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising inorganic material comprising silica or silicate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/30—Extraction; Separation; Purification by precipitation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
CL2014003430A 2010-05-26 2014-12-17 Método para producir una preparacion de inmunoglobulina con un rendimiento mejorado CL2014003430A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AU2010202125A AU2010202125B1 (en) 2010-05-26 2010-05-26 A method to produce an immunoglobulin preparation with improved yield

Publications (1)

Publication Number Publication Date
CL2014003430A1 true CL2014003430A1 (es) 2015-05-04

Family

ID=42727304

Family Applications (3)

Application Number Title Priority Date Filing Date
CL2012003291A CL2012003291A1 (es) 2010-05-26 2012-11-23 Metodo para reducir la cantidad de una serina proteasa o de un zimógeno de serina proteasa en una composicion de proteinas derivadas de plasma de interés; metodo para preparar una composicion del factor h con una cantidad reducida de una serina proteasa o de un zimógeno de serina proteasa; metodo para preparar composicion de un inhibidor de inter-alfa-tripsina.
CL2012003290A CL2012003290A1 (es) 2010-05-26 2012-11-23 Metodo para preparar una composicion enriquecida en igg a partir de plasma; composicion acuosa de igg; composicion farmaceutica que comprende dicha composicion acuosa; uso de dicha composicion para tratar enfermedad autoinmune o infeccion aguda
CL2014003430A CL2014003430A1 (es) 2010-05-26 2014-12-17 Método para producir una preparacion de inmunoglobulina con un rendimiento mejorado

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CL2012003291A CL2012003291A1 (es) 2010-05-26 2012-11-23 Metodo para reducir la cantidad de una serina proteasa o de un zimógeno de serina proteasa en una composicion de proteinas derivadas de plasma de interés; metodo para preparar una composicion del factor h con una cantidad reducida de una serina proteasa o de un zimógeno de serina proteasa; metodo para preparar composicion de un inhibidor de inter-alfa-tripsina.
CL2012003290A CL2012003290A1 (es) 2010-05-26 2012-11-23 Metodo para preparar una composicion enriquecida en igg a partir de plasma; composicion acuosa de igg; composicion farmaceutica que comprende dicha composicion acuosa; uso de dicha composicion para tratar enfermedad autoinmune o infeccion aguda

Country Status (25)

Country Link
US (6) US8993734B2 (es)
EP (6) EP2554160B1 (es)
JP (6) JP5876474B2 (es)
KR (3) KR101593265B1 (es)
CN (5) CN102970975B (es)
AR (4) AR076800A1 (es)
AU (8) AU2010202125B1 (es)
BR (2) BR112012029893B1 (es)
CA (2) CA2800155A1 (es)
CL (3) CL2012003291A1 (es)
CO (2) CO6660438A2 (es)
DK (3) DK2554160T3 (es)
EA (4) EA034602B1 (es)
ES (4) ES2525492T3 (es)
HK (1) HK1213790A1 (es)
HR (3) HRP20141109T1 (es)
HU (1) HUE064400T2 (es)
IL (2) IL223150A0 (es)
MX (4) MX364252B (es)
MY (3) MY160551A (es)
PL (4) PL2445482T3 (es)
PT (3) PT2445482E (es)
SG (3) SG185724A1 (es)
TW (3) TWI531577B (es)
WO (1) WO2011149472A1 (es)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI489994B (zh) 2008-03-17 2015-07-01 Baxter Healthcare Sa 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法
WO2011034604A2 (en) * 2009-09-17 2011-03-24 Baxter Healthcare, S.A. Stable co-formulation of hyaluronidase and immunoglobulin, and methods of use thereof
US10787701B2 (en) 2010-04-05 2020-09-29 Prognosys Biosciences, Inc. Spatially encoded biological assays
AU2010202125B1 (en) 2010-05-26 2010-09-02 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation with improved yield
WO2011150284A2 (en) 2010-05-26 2011-12-01 Baxter International Inc. Removal of serine proteases by treatment with finely divided silicon dioxide
US8841248B2 (en) * 2010-07-23 2014-09-23 Baxter International Inc. Manufacture of inter-alpha-inhibitor (IaIp) from plasma
AU2011364724B2 (en) * 2011-04-08 2016-11-17 Universidad De Costa Rica Method for producing injectable formulations of blood-derived protein materials, and materials obtained using said method
PT2791675T (pt) 2011-12-13 2018-07-27 Baxalta Inc Medição de autoanticorpos em condições de baixa condutividade
TWI629283B (zh) * 2012-02-23 2018-07-11 巴克斯歐塔公司 來自血漿中的免疫球蛋白之ｉ-ｉｖ-１部分沉澱
RU2487725C1 (ru) * 2012-03-15 2013-07-20 Федеральное государственное унитарное предприятие "Научно-производственное объединение по медицинским иммунобиологическим препаратам "Микроген" Министерства здравоохранения Российской Федерации (ФГУП "НПО "Микроген" Минздрава России) Способ получения концентрированного иммуноглобулинового препарата для подкожного введения
CN103197053B (zh) * 2013-03-15 2015-02-18 上海市血液中心 一种抗IgA抗体检测试剂盒
AU2013203043B2 (en) 2013-03-15 2016-10-06 Takeda Pharmaceutical Company Limited Methods to produce a human plasma-derived igg preparation enriched in brain disease-related natural iggs
CN104072601A (zh) * 2014-07-03 2014-10-01 成都蓉生药业有限责任公司 血液制品中fii沉淀的制备方法
CN104086642A (zh) * 2014-07-03 2014-10-08 成都蓉生药业有限责任公司 血液制品中fi+iii上清的制备方法
CN104086646B (zh) * 2014-07-03 2018-10-09 成都蓉生药业有限责任公司 血液制品中fv沉淀的制备方法
GB201413227D0 (en) * 2014-07-25 2014-09-10 Bioproducts Lab Ltd Process
WO2016064955A1 (en) 2014-10-21 2016-04-28 The General Hospital Corporation Methods of diagnosis and treatment of tuberculosis and infection
CN204424090U (zh) 2014-11-28 2015-06-24 比亚迪股份有限公司 薄膜电容器
WO2016161421A1 (en) * 2015-04-02 2016-10-06 Kieu Hoang A method of manufacturing intravenous immunoglobulin from fraction iii
CN107921080A (zh) * 2015-04-02 2018-04-17 K·黄 由组分iii制造并纯化出用于静脉注射的凝血酶原复合物浓缩剂的方法以及治疗和预防具有抑制剂的a型血友病或感染了hiv‑1和hiv‑2的b型血友病患者的方法
US20160289301A1 (en) * 2015-04-02 2016-10-06 Kieu Hoang Process of cloning and further purification to make a recombinant intravenous immunoglobulin
US20170233458A1 (en) * 2015-09-29 2017-08-17 Kieu Hoang Method of manufacturing intravenous immunoglobulin from fraction iii
US20170232079A1 (en) * 2015-10-06 2017-08-17 Kieu Hoang Method of manufacturing prothrombin complex concentrate from fraction iii and non-prothrombin complex concentrate from fraction iv
CN106800583A (zh) * 2015-11-26 2017-06-06 上海洲跃生物科技有限公司 一种速溶无析出的冻干人纤维蛋白原制备工艺
EP3275897A1 (en) * 2016-07-27 2018-01-31 Biotest AG Process for preparing immunoglobulin compositions
KR20190053908A (ko) * 2016-09-16 2019-05-20 로이코케어 아게 가공 동안 바이오 의약품의 안정화를 위한 신규한 방법
EP3512496B1 (en) 2016-09-16 2025-07-30 Leukocare Ag A novel method for producing low viscous and highly concentrated biopharmaceutical drug products in liquid formulation
US11166915B2 (en) 2016-09-16 2021-11-09 Leukocare Ag Method for obtaining efficient viral vector-based compositions for vaccination or gene therapy
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
US20200055922A1 (en) * 2017-04-21 2020-02-20 Csl Behring Ag Immunoglobulin products for use in the treatment of chronic inflammatory demyelinating polyneuropathy
CA3080656A1 (en) 2017-10-30 2019-05-09 Baxalta GmbH Environmentally compatible detergents for inactivation of lipid-enveloped viruses
CN111511756B (zh) * 2017-12-19 2023-11-03 康诺贝林伦瑙有限公司 使用烷基糖苷类进行蛋白质纯化和病毒灭活
AU2019250882B2 (en) * 2018-04-12 2025-10-16 Amgen Inc. Methods for making stable protein compositions
CN108733099B (zh) * 2018-05-31 2020-08-11 上海药明生物技术有限公司 低pH孵育和中和的自动调节系统及方法
WO2021072137A1 (en) * 2019-10-11 2021-04-15 Baxalta Incorporated Heparin-insensitive assay for factor xla
CN114667151B (zh) * 2019-11-04 2025-05-23 万能溶剂有限公司 用于肌肉再生的血浆级分
WO2021099529A1 (en) * 2019-11-20 2021-05-27 Csl Behring Ag Method for extracting a protein from a precipitate and method for precipitating impurities
MX2022011950A (es) * 2020-03-31 2022-10-21 Takeda Pharmaceuticals Co Metodo para producir una preparacion de inmunoglobulina a partir de plasma con reduccion del inhibidor de c-1.
JP2023526738A (ja) 2020-04-10 2023-06-23 プラズマ テクノロジーズ エルエルシー タンパク質の単純化した高効率単離のための組成物および方法
CN111961130B (zh) * 2020-08-31 2021-09-10 华兰生物工程重庆有限公司 一种从血浆中提取并分离IgM和IgG的方法
CA3189976A1 (en) * 2020-10-01 2022-04-07 Takeda Pharmaceutical Company Limited Plasma fractionation process utilizing spray-dried human plasma
EP4271706A4 (en) * 2020-12-28 2025-01-15 Plasma Technologies LLC SYSTEMS AND METHODS FOR THE ISOLATION OF IMMUNGLOBULIN G ON A PROCESS SCALE
CN112574296B (zh) * 2020-12-30 2023-05-19 中国医学科学院输血研究所 一种模拟IVIg的多人份混合人血浆IgG样品的分离纯化方法
MX2024001187A (es) 2021-07-29 2024-02-27 Csl Behring Ag Metodo para purificar inmunoglobulina g y usos de la misma.
EP4423109A4 (en) 2021-10-27 2025-12-24 Plasma Tech Llc COMPOSITIONS AND METHODS FOR ISOLATING PROTEINS
KR102779378B1 (ko) * 2022-01-05 2025-03-12 한양대학교 에리카산학협력단 1-알릴이소크로만 유도체와 이의 제조방법
KR20230121373A (ko) * 2022-02-11 2023-08-18 주식회사 녹십자 인자 xiii의 정제방법
CN118891279A (zh) 2022-03-07 2024-11-01 武田药品工业株式会社 临床人IgG产品的亲和色谱生产
JP2025509154A (ja) 2022-03-08 2025-04-11 エクアシールド メディカル リミテッド ロボット医薬品調製システムにおける流体移送ステーション
CN119300842A (zh) 2022-05-02 2025-01-10 武田药品工业株式会社 通过超滤从血浆制备科恩池浓缩物的方法
IL317372A (en) 2022-06-22 2025-02-01 Ageronix SA Alpha1-antitrypsin for use in the treatment of diseases and disorders of the nervous system such as chronic demyelinating polyneuropathy
AU2024247735A1 (en) 2023-03-29 2025-10-30 Csl Behring Ag Methods of identifying immunoglobulin associated with adverse reactions
WO2025008781A1 (en) 2023-07-04 2025-01-09 Csl Behring Ag Method of purification
WO2025068923A2 (en) 2023-09-26 2025-04-03 Takeda Pharmaceutical Company Limited IMMUNOGLOBULIN FORMULATIONS DEPLETED IN IgA
WO2025085544A1 (en) * 2023-10-17 2025-04-24 Plasma Technologies, Llc Integrated process for isolation of plasma proteins
PL448469A1 (pl) * 2024-04-30 2025-11-03 Deveris Polska Spółka Z Ograniczoną Odpowiedzialnością Przedmiotem wynalazku jest sposób wzbogacania preparatów plazmy krwi drobiowej w immunoglobulinę G (IgG)
WO2025229607A1 (en) 2024-05-03 2025-11-06 Csl Behring Ag Systems and methods for solid-liquid separation

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2390074A (en) * 1942-02-09 1945-12-04 Research Corp Protein product and process
SE348942B (es) 1970-06-02 1972-09-18 Statens Bakteriologiska Labor
US4056614A (en) 1972-09-22 1977-11-01 Marc Bonneau Immunity depressant medicine
US3998946A (en) * 1975-04-23 1976-12-21 The Regents Of The University Of Minnesota Fibrinogen-free plasminogen-plasmin-free plasma and method of preparing and using same
DE2801123C2 (de) * 1977-01-26 1986-01-02 Armour Pharma GmbH & Co KG, 3440 Eschwege Verfahren zur Herstellung eines intravenös applizierbaren Serumeiweiß-Präparates
US4296027A (en) * 1977-08-31 1981-10-20 The Regents Of The University Of Minnesota Pure intravenous human and animal gamma globulins
US4136094A (en) 1977-08-31 1979-01-23 The Regents Of The University Of Minnesota Preparation of intravenous human and animal gamma globulins and isolation of albumin
US4357272A (en) * 1978-03-22 1982-11-02 The South African Inventions Development Corporation Recovering purified antibodies from egg yolk
US4550019A (en) * 1978-03-22 1985-10-29 South Africa Inventions Development Corporation Manufacture and use of fowl egg antibodies
DE2901822A1 (de) * 1979-01-18 1980-07-31 Biotest Serum Institut Gmbh Verfahren zur herstellung einer fuer die intravenoese applikation geeigneten immunglobulinloesung, die igm in ankonzentrierter form enthaelt
DE2902158A1 (de) 1979-01-20 1980-07-31 Biotest Serum Institut Gmbh Verfahren zur herstellung von fibrinogen, einem die gerinnungsfaktoren ii, vii, ix und x enthaltenden prothrombinkomplex, antithrombin iii und einer loesung von lagerstabilen serumproteinen
US4228154A (en) 1979-02-26 1980-10-14 Armour Pharmaceutical Company Purification of plasma albumin by ion exchange chromatography
US4378346A (en) * 1979-08-15 1983-03-29 Tankersley Donald L Intravenously injectable solution of plasma protein fraction free from bradykinin, kininogen and prekallikrein activators and processes for its production
US4499073A (en) * 1981-08-24 1985-02-12 Cutter Laboratories, Inc. Intravenously injectable immune serum globulin
JPS5855432A (ja) 1981-09-29 1983-04-01 Fujirebio Inc 静脈注射用免疫グロブリンの製法
US4439358A (en) 1982-06-17 1984-03-27 Miles Laboratories, Inc. Method of preparing alpha-1-proteinase inhibitor
US4624780A (en) 1982-06-28 1986-11-25 Alpha Therapeutic Corporation Fractionation of blood plasma
DE3247150A1 (de) 1982-12-21 1984-06-28 Biotest-Serum-Institut Gmbh, 6000 Frankfurt Gerinnungsaktive plasmaproteinloesung, verfahren zu ihrer herstellung und ihre verwendung zur behandlung von stoerungen des haemostasesystems
DK166763C (da) 1983-03-16 1993-07-12 Immuno Ag Immunoglobulin-g-holdig fraktion
DE3523615A1 (de) 1985-07-02 1987-01-15 Cytomed Medizintechnik Medizinisches geraet, insbesondere kanuele, katheter oder implantat
US5061237A (en) 1985-07-02 1991-10-29 Cytomed Medizintechnik Gmbh Method of purifying whole blood
JPH0742235B2 (ja) 1985-11-08 1995-05-10 三共株式会社 自己免疫性疾病の予防・治療剤
US5136094A (en) 1988-03-10 1992-08-04 Air Products And Chemicals, Inc. Process for the synthesis of secondary formamides
US5055447A (en) 1988-07-28 1991-10-08 Genentech, Inc. Method and compositions for the treatment and prevention of septic shock
JP2871709B2 (ja) 1988-11-21 1999-03-17 住友製薬株式会社 免疫グロブリンｇ結合活性を有する新規な蛋白質プロテインｈ、該蛋白質をコードする遺伝子及び該蛋白質の製造法
US5177194A (en) 1990-02-01 1993-01-05 Baxter International, Inc. Process for purifying immune serum globulins
EP0440509A3 (en) * 1990-02-02 1991-12-18 Common Services Agency Novel cell growth medium components and process for producing same
DK0447585T4 (da) * 1990-03-22 2003-09-01 Biotest Pharma Gmbh Fremgangsmåde til fremstilling af et intravenøst tolerant immunglobulin-G-præparat
US5130451A (en) * 1991-03-28 1992-07-14 Amoco Corporation Process for preparing carboxyaryl phosphates
US5324425A (en) * 1992-08-26 1994-06-28 Ellison Billy L Method and apparatus for removing solids from aqueous wash solutions
FR2706466B1 (fr) 1993-06-14 1995-08-25 Aetsrn Concentré d'immunoglobulines G à usage thérapeutique et procédé de production dudit concentré.
FR2711371B1 (fr) 1993-10-18 1995-12-29 Aetsrn Procédé de préparation d'un concentré d'inter-alpha-trypsine inhibiteur à usage thérapeutique et concentré obtenu.
US5610285A (en) 1994-08-24 1997-03-11 Bayer Corporation Purification of α-1 proteinase inhibitor using novel chromatographic separation conditions
DE4435485C1 (de) 1994-10-04 1996-03-21 Immuno Ag Verfahren zur Gewinnung von hochreinem von Willebrand-Faktor
AUPN858596A0 (en) * 1996-03-08 1996-04-04 Csl Limited Filtration of plasma precipitates using cellulose filter aid
TW491855B (en) * 1996-08-07 2002-06-21 Csl Ltd Purification of immunoglobulins
US5783640A (en) * 1997-03-04 1998-07-21 The Goodyear Tire & Rubber Company Rubber compositions containing a disodium salt of 2, 2'-dithiosalicyclic acid
TW541179B (en) 1997-03-19 2003-07-11 Green Cross Corp Process for preparing immunoglobulin preparation
GB9705810D0 (en) 1997-03-20 1997-05-07 Common Services Agency Intravenous immune globulin
AT407114B (de) 1997-06-10 2000-12-27 Immuno Ag Alpha 1-antitrypsin-präparation sowie verfahren zu deren herstellung
US5886154A (en) * 1997-06-20 1999-03-23 Lebing; Wytold R. Chromatographic method for high yield purification and viral inactivation of antibodies
PT911037E (pt) 1997-10-23 2002-12-31 Mitsubishi Pharma Corp Preparacao de imunoglobulina armazenavel a temperatura ambiente para injeccao intravenosa
US20020114802A1 (en) 1998-02-10 2002-08-22 Tjellstrom Bo Arthur Einar Oral immunoglobulin treatment for inflammatory bowel disease
AT406873B (de) 1998-02-25 2000-10-25 Immuno Ag Verfahren zur abreicherung von pathogenen aus proteinhaltigen lösungen
DE19932782A1 (de) * 1999-07-14 2001-01-18 Biotest Pharma Gmbh Verfahren zur chromatographischen Fraktionierung von Plasma oder Serum, so erhaltene Präparate und deren Verwendung
ATE290837T1 (de) 1999-10-21 2005-04-15 Alcon Inc Medikamentenversorgung der sub-tenon
DE10008519C1 (de) 2000-02-21 2001-07-12 Dica Technologies Ag Verfahren und Kommunikationseinrichtungen zum Aufbau von gesicherten E-Mail-Verkehr zwischen Mail-Domains des Internet
DE10008619A1 (de) * 2000-02-24 2001-09-06 Immuno Vet As Lynge Mikroorganismenfreies IgG-Präparat, Verfahren zu seiner Herstellung und seine Verwendung in der Tieraufzucht und in der Tiermast
SE0001128D0 (sv) 2000-03-30 2000-03-30 Amersham Pharm Biotech Ab A method of producing IgG
US20020098182A1 (en) 2000-09-28 2002-07-25 Richard Weisbart Treatment of immune-mediated diseases by oral administration of plasma fractions enriched in immunoglobulin G
WO2002030983A2 (de) 2000-10-13 2002-04-18 Octapharma Ag Bikunin enthaltende plasmafraktion, verfahren zu ihrer herstellung und ihrer verwendung
FR2824568B1 (fr) 2001-05-11 2004-04-09 Lab Francais Du Fractionnement Procede de preparation de concentres d'immunoglobulines humaines a usage therapeutique
JP2005508338A (ja) 2001-10-04 2005-03-31 プロテイン セラピューティクス、インク． 免疫性疾患を処置するためのガンマグロブリンの使用
US6893639B2 (en) 2001-10-19 2005-05-17 Hemacare Corporation Method for high yield purification of immune globulins from blood plasma and blood plasma intermediates
US7777006B2 (en) 2002-12-31 2010-08-17 Csl Behring L.L.C. Method for purification of alpha-1-antitrypsin
CA2525224A1 (en) * 2003-05-23 2004-12-02 Michael Bech Jensen Protein stabilization in solution
WO2005012354A1 (en) 2003-07-31 2005-02-10 Zlb Behring Gmbh Method for extending the half-life of fviii
US20050054003A1 (en) 2003-09-10 2005-03-10 Stenland Christopher J. Prion clearance using particulate metal oxides
EP1691820A4 (en) 2003-11-08 2010-03-03 Prothera Biolog PREPARATION AND COMPOSITION OF INTER-ALPHA INHIBITOR PROTEINS FROM HUMAN PLASMA FOR THERAPEUTIC USE
US20070244305A1 (en) 2004-01-30 2007-10-18 Suomen Punainen Risti Veripalvelu Process for The Manufacture of Virus Safe Immunoglobulin
UA87836C2 (ru) 2004-02-27 2009-08-25 Октафарма Аг Способ получения очищенных, безопасных с вирусологической точки зрения препаратов антител
NZ608860A (en) 2005-02-14 2014-10-31 Univ Iowa Res Found Methods and reagents for treatment and diagnosis of age-related macular degeneration
US8715649B2 (en) 2005-06-07 2014-05-06 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods of use for alpha-1 antitrypsin having no significant serine protease inhibitor activity
US7807435B2 (en) 2005-08-11 2010-10-05 Baxter International Inc. Method for the purification of alpha-1 proteinase inhibitor (a1PI)
WO2007038995A1 (en) 2005-09-19 2007-04-12 Csl Behring Gmbh Factor h for the treatment of chronic nephropathies and production thereof
FR2894145B1 (fr) 2005-12-07 2008-10-17 Lab Francais Du Fractionnement Utilisation de facteur h du complement a titre de medicament
EP1987054A1 (en) * 2006-01-25 2008-11-05 Octapharma AG Purification and use of a factor for supporting wound healing
US8476234B2 (en) 2006-02-03 2013-07-02 Prolor Biotech Inc. Long-acting coagulation factors and methods of producing same
EP1852443A1 (en) * 2006-05-05 2007-11-07 Leukocare AG Biocompatible three dimensional matrix for the immobilization of biological substances
DE102007001521A1 (de) * 2007-01-10 2008-07-17 Matthias, Torsten, Dr. Verwendung von Cohn-Oncley-Fraktionen II und II/III zur Behandlung des systemischen Lupus erythematodes
WO2008113589A1 (en) * 2007-03-20 2008-09-25 Csl Behring Gmbh Methods for industrial scale production of therapeutic complement factor h preparations from human plasma
DE202007004346U1 (de) 2007-03-21 2007-10-31 Rehau Ag + Co Rohranordnung
JP2010524971A (ja) * 2007-04-20 2010-07-22 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・コロラド，ア・ボディー・コーポレイト 顕著なセリンプロテアーゼ阻害剤活性を有さないアルファ−１アンチトリプシン
ES2392569T3 (es) 2007-06-13 2012-12-11 Csl Behring Gmbh Uso de preparaciones FVIII estabilizadas VWF para administración extravascular en la terapia y el tratamiento profiláctico de trastornos de hemorragias
EP2522754B1 (en) 2007-08-13 2014-04-02 Baxter International Inc. IVIG modulation of chemokines for treatment of Multiple Sclerosis, Alzheimer's disease, and Parkinson's disease
AU2008307144B2 (en) * 2007-10-02 2012-12-20 Csl Limited Therapeutic antibody purification method and method of use
BRPI0821474B8 (pt) 2007-12-28 2021-05-25 Baxalta GmbH formulação farmacêutica líquida estável
CN101249265B (zh) * 2008-04-11 2010-10-27 三九集团湛江开发区双林药业有限公司 静脉注射用人乙肝免疫球蛋白及其制备方法
DK2291654T3 (en) 2008-05-28 2018-06-14 Prothera Biologics Inc PREPARATION AND COMPOSITION OF BLOOD INTER-ALPHA INHIBITOR PROTEINS
KR101648734B1 (ko) 2008-06-24 2016-08-18 체에스엘 베링 게엠베하 연장된 생체내 반감기를 갖는 인자 ｖｉｉｉ, 폰 빌레브란트 인자 또는 이들의 복합체
CN201169579Y (zh) * 2008-06-30 2008-12-24 山东泰邦生物制品有限公司 一种人血白蛋白分离用乙醇雾化扩散装置
EP2349314B1 (en) 2008-10-21 2013-02-27 Baxter International Inc. Lyophilized recombinant vwf formulations
WO2010056909A1 (en) 2008-11-12 2010-05-20 Baxter International Inc. Purification of butyrylcholinesterase using membrane adsorption
WO2010138736A2 (en) 2009-05-27 2010-12-02 Baxter International Inc. A method to produce a highly concentrated immunoglobulin preparation for subcutaneous use
WO2011011753A1 (en) 2009-07-23 2011-01-27 Baxter International Inc. Manufacture of factor h (fh) and fh-derivatives from plasma
WO2011150284A2 (en) * 2010-05-26 2011-12-01 Baxter International Inc. Removal of serine proteases by treatment with finely divided silicon dioxide
AU2010202125B1 (en) 2010-05-26 2010-09-02 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation with improved yield
HRP20250948T1 (hr) 2010-07-08 2025-10-10 Takeda Pharmaceutical Company Limited Postupak proizvodnje rekombinantnog visokomolekulskog vwf u kulturi stanica
US8841248B2 (en) 2010-07-23 2014-09-23 Baxter International Inc. Manufacture of inter-alpha-inhibitor (IaIp) from plasma

Also Published As

Publication number Publication date
TW201202263A (en) 2012-01-16
IL223149A (en) 2017-02-28
EP2796128A1 (en) 2014-10-29
US20210403504A1 (en) 2021-12-30
CN109180776B (zh) 2022-12-13
US20150133644A1 (en) 2015-05-14
AU2011258111B2 (en) 2016-02-11
TWI531577B (zh) 2016-05-01
CL2012003290A1 (es) 2013-10-18
CN102970975B (zh) 2015-05-06
TW201542584A (zh) 2015-11-16
AU2010224461A1 (en) 2010-10-21
MY173299A (en) 2020-01-14
EA201291367A1 (ru) 2013-09-30
AU2018201371B2 (en) 2019-10-31
JP2013527201A (ja) 2013-06-27
MY161617A (en) 2017-04-28
HRP20150484T1 (hr) 2015-08-14
CO6660438A2 (es) 2013-04-30
MX2012013689A (es) 2013-01-28
MY160551A (en) 2017-03-15
PL2575762T3 (pl) 2015-01-30
MX349815B (es) 2017-08-09
HK1215931A1 (zh) 2016-09-30
EP2445482B1 (en) 2014-08-27
IL223150A0 (en) 2013-02-03
CA2800155A1 (en) 2011-12-01
EA201500848A1 (ru) 2016-06-30
ES2959234T3 (es) 2024-02-22
KR101593265B1 (ko) 2016-02-11
AU2018201371A1 (en) 2018-03-22
EA025826B1 (ru) 2017-02-28
AR076800A1 (es) 2011-07-06
EP2554160B1 (en) 2015-02-25
JP2018080207A (ja) 2018-05-24
EP2575762A2 (en) 2013-04-10
WO2011149472A1 (en) 2011-12-01
JP2013528183A (ja) 2013-07-08
HRP20141109T1 (hr) 2014-12-19
PL2554160T3 (pl) 2015-07-31
HK1181682A1 (en) 2013-11-15
US20110293638A1 (en) 2011-12-01
US20240117009A1 (en) 2024-04-11
CO6660439A2 (es) 2013-04-30
AU2021286395A1 (en) 2022-01-20
JP6592120B2 (ja) 2019-10-16
CN104958761B (zh) 2021-01-01
EP2554160A1 (en) 2013-02-06
CN104840946A (zh) 2015-08-19
AU2024204779A1 (en) 2024-08-01
AU2021286395B2 (en) 2024-04-11
CL2012003291A1 (es) 2013-10-04
BR112012029897A2 (pt) 2016-08-16
HK1183449A1 (en) 2013-12-27
BR112012029893A2 (pt) 2019-05-28
US20180118782A1 (en) 2018-05-03
KR20130080450A (ko) 2013-07-12
EP2445482A1 (en) 2012-05-02
CN104958761A (zh) 2015-10-07
JP5876474B2 (ja) 2016-03-02
KR101716534B1 (ko) 2017-03-14
EP2803349A1 (en) 2014-11-19
CN102970975A (zh) 2013-03-13
TWI504607B (zh) 2015-10-21
PT2554160E (pt) 2015-06-11
HK1170168A1 (en) 2013-02-22
EP2803349B1 (en) 2023-09-27
HK1213790A1 (zh) 2016-07-15
DK2445482T3 (da) 2014-09-22
JP2016155798A (ja) 2016-09-01
EA201691558A1 (ru) 2017-05-31
JP2017014297A (ja) 2017-01-19
HK1203838A1 (en) 2015-11-06
HUE064400T2 (hu) 2024-03-28
AU2011258111A1 (en) 2012-12-13
IL223149A0 (en) 2013-02-03
MX364252B (es) 2019-04-17
JP5866345B2 (ja) 2016-02-17
KR20130109016A (ko) 2013-10-07
EA034530B1 (ru) 2020-02-18
PT2575762E (pt) 2014-07-28
US20130101579A1 (en) 2013-04-25
AU2016202973B2 (en) 2017-12-07
US8993734B2 (en) 2015-03-31
AU2010224461B2 (en) 2011-08-04
EP4039249A1 (en) 2022-08-10
AR121861A2 (es) 2022-07-20
AU2020200373B2 (en) 2022-01-13
EP2575762B1 (en) 2014-07-09
EA023446B1 (ru) 2016-06-30
HRP20140944T1 (hr) 2014-12-05
JP6363676B2 (ja) 2018-07-25
EA034602B1 (ru) 2020-02-25
EP2803349C0 (en) 2023-09-27
TWI543989B (zh) 2016-08-01
US11136350B2 (en) 2021-10-05
DK2554160T3 (da) 2015-04-27
PT2445482E (pt) 2014-11-03
PL2445482T3 (pl) 2015-01-30
AU2020200373A1 (en) 2020-02-13
SG10201505161SA (en) 2015-08-28
KR101647617B1 (ko) 2016-08-10
JP2016053016A (ja) 2016-04-14
BR112012029893B1 (pt) 2022-09-06
US8940877B2 (en) 2015-01-27
ES2536093T3 (es) 2015-05-20
EA201291355A1 (ru) 2013-04-30
AR082093A1 (es) 2012-11-14
MX2019004482A (es) 2019-08-30
TW201141879A (en) 2011-12-01
SG185725A1 (en) 2012-12-28
CA2800272A1 (en) 2011-12-01
MX2012013682A (es) 2013-01-28
DK2575762T3 (da) 2014-10-13
CN103068365A (zh) 2013-04-24
MX337028B (es) 2016-02-09
AR114228A2 (es) 2020-08-05
CN109180776A (zh) 2019-01-11
SG185724A1 (en) 2013-01-30
CN103068365B (zh) 2015-07-08
AU2016202973A1 (en) 2016-05-26
KR20160014119A (ko) 2016-02-05
AU2010202125B1 (en) 2010-09-02
ES2525492T3 (es) 2014-12-23
PL2803349T3 (pl) 2024-02-26
ES2505465T3 (es) 2014-10-10

Similar Documents

Publication Publication Date Title
CL2014003430A1 (es) Método para producir una preparacion de inmunoglobulina con un rendimiento mejorado
NO2023024I1 (no) Spesolimab, an ant-IL-36R antibody
IL282796B (en) Sample array coding for low-delay
PT2608541T (pt) Método para descodificar intra-previsões
DK3178851T3 (da) Anti-cd40-antistoffer
ES2858225T8 (es) Procedimiento para producir elementos estructurales templados
BR112013001513A2 (pt) método para otimizar a performance de veículo
EP2761522A4 (en) OAUTH FRAME
HUE055717T2 (hu) Eljárás antitestek elõállítására
BR112012015988A2 (pt) método
BR112014013034A2 (pt) método para produzir um anticorpo
BR112012020964A2 (pt) método de produção de imunoglobulina
BR112014009795A2 (pt) método
BR112014007958A2 (pt) método
CO6980628A2 (es) Método de fabricación de núcleos de devanados para configuraciones de núcleos divididas
BR112014001765A2 (pt) método
BR112014001237A2 (pt) método
BR112013031026A2 (pt) terminal de conexão e método para fabricação do terminal de conexão
BR112013003535A2 (pt) método para formar espuma
BR112013007237A2 (pt) ''método para produzir um anticorpo anti-ig-1r''
BR112012023891A2 (pt) método
BR112014007794A2 (pt) método para otimização de desempenho de solda
BR112014009831A2 (pt) método de manufatura de núcleo de estator, e, núcleo de estator
LT2742068T (lt) Nauji antikūnai prieš fosforilcholiną
CL2013000688A1 (es) Procedimiento para obtener una composicion de igg a partir de una composicion de igg parcialmente purificada.